NEW YORK (GenomeWeb News) – Fluorotechnics today said that it is offering a one for five non-renouncable pro rata rights issue at A$.30 per share that it expects will bring in proceeds of A$1.8 million (US$1.6 million).

The Australian supplier of fluorescence and other protein detection technologies said that the shares are priced at a 14 percent discount to its closing price on the Australian Stock Exchange yesterday.

Fluorotechnics intends to use the proceeds for sales and marketing initiatives and as working capital.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.